Search research articles
Contact Us
Filters
Showing results (141-150 of 170) with videos related to
Page
of 17
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors
Aaron Smith, Zhi-Jie Ni, Daniel Poon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Alwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Cancer Discovery
|
December 18, 2016
Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
Weiyi Toy, Hazel Weir, Pedram Razavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Cell Metabolism
|
October 3, 2006
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance
Maura Agostini, Erik Schoenmakers, Catherine Mitchell, et al.
The Journal of Organic Chemistry
|
April 23, 2024
Challenges with the Synthesis of a Macrocyclic Thioether Peptide: From Milligram to Multigram Using Solid Phase Peptide Synthesis (SPPS)
James Kempson, Rulin Zhao, Joseph Pawluczyk, et al.
Molecular Cancer Therapeutics
|
February 2, 2026
Preclinical to clinical translation of pharmacokinetic-pharmacodynamic relationship in EGFR Exon20Ins mutations: a modelling framework for irreversible inhibitors
Adriana Savoca, Diana Zindel, Radoslaw Polanski, et al.
Molecular Cancer Therapeutics
|
September 20, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, et al.
Cell Reports. Medicine
|
August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Aisha M Swaih, Sara Talbot, Adriana Savoca, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example
Markus Boehm, David Hepworth, Paula M Loria, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 170) with videos related to
Sort By:
Page
of 17
Bioorganic & Medicinal Chemistry Letters
|
November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors
Aaron Smith, Zhi-Jie Ni, Daniel Poon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Alwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Cancer Discovery
|
December 18, 2016
Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists
Weiyi Toy, Hazel Weir, Pedram Razavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Cell Metabolism
|
October 3, 2006
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance
Maura Agostini, Erik Schoenmakers, Catherine Mitchell, et al.
The Journal of Organic Chemistry
|
April 23, 2024
Challenges with the Synthesis of a Macrocyclic Thioether Peptide: From Milligram to Multigram Using Solid Phase Peptide Synthesis (SPPS)
James Kempson, Rulin Zhao, Joseph Pawluczyk, et al.
Molecular Cancer Therapeutics
|
February 2, 2026
Preclinical to clinical translation of pharmacokinetic-pharmacodynamic relationship in EGFR Exon20Ins mutations: a modelling framework for irreversible inhibitors
Adriana Savoca, Diana Zindel, Radoslaw Polanski, et al.
Molecular Cancer Therapeutics
|
September 20, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, et al.
Cell Reports. Medicine
|
August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Aisha M Swaih, Sara Talbot, Adriana Savoca, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example
Markus Boehm, David Hepworth, Paula M Loria, et al.
Page
of 17